Kinetics and regulation of cytochrome P450-mediated etoposide metabolism.

Etoposide is a DNA topoisomerase II inhibitor widely used in the treatment of a variety of malignancies that is also associated with therapy-related leukemia. The cytochrome P450 (P450)-derived catechol and quinone metabolites of etoposide may be important in the damage to the MLL (mixed lineage leukemia) gene and other genes resulting in leukemia-associated chromosomal translocations. Kinetic analysis of catechol formation by recombinant P450s was determined using liquid chromatography/selected reaction monitoring/mass spectrometry. CYP3A4 was found to play a major role in etoposide metabolism (K(m) = 77.7 +/- 27.8 microM; V(max) = 314 +/- 84 pmol of catechol/min/nmol of P450). However, CYP3A5 (K(m) = 13. 9 +/- 3.1 microM; V(max) = 19.4 +/- 0.4 pmol of catechol/min/nmol of P450) may be involved in etoposide metabolism at therapeutic concentrations of free drug. Other P450s do not appear to be involved in etoposide catechol formation. Real-time polymerase chain reaction and Western blot analysis revealed significantly increased CYP3A4 mRNA and protein levels in hepatocytes treated with 10 microM rifampicin compared with untreated cells, but only modest effects of rifampicin on CYP3A5 induction. Etoposide (40, 5, 1, and 0.25 microM) caused a slight increase in CYP3A4 mRNA in three of five batches of hepatocytes but did not result in proportionately increased CYP3A4 protein levels. At high concentrations, etoposide induced only a modest increase in CYP3A5 mRNA and protein levels in four of five batches of hepatocytes. Alternatively, coadministration of other drugs with etoposide may account for the increase in etoposide catechol formation during therapy with etoposide.

[1]  K. Hande,et al.  Etoposide: four decades of development of a topoisomerase II inhibitor. , 1998, European journal of cancer.

[2]  P. Nowell,et al.  Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Kim,et al.  Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. , 2002, Molecular pharmacology.

[4]  C. Felix.  Secondary leukemias induced by topoisomerase-targeted drugs. , 1998, Biochimica et biophysica acta.

[5]  D. Dunbar,et al.  Induction of CYP1A by benzo[k]fluoranthene in human hepatocytes: CYP1A1 or CYP1A2? , 2001, Archives of biochemistry and biophysics.

[6]  F. Behm,et al.  Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. , 2002, Pharmacogenetics.

[7]  P. Creaven.  The clinical pharmacology of VM26 and VP16-213 , 1982, Cancer Chemotherapy and Pharmacology.

[8]  J. Sinkule.  Etoposide: A Semisynthetic Epipodophyllotoxin Chemistry, Pharmacology, Pharmacokinetics, Adverse Effects and Use as an Antineoplastic Agent , 1984, Pharmacotherapy.

[9]  M. Leyland,et al.  Metoclopramide in the reduction of nausea and vomiting associated with combined chemotherapy , 2004, Cancer Chemotherapy and Pharmacology.

[10]  D. Grzanka,et al.  Cytoskeletal reorganization during process of apoptosis induced by cytostatic drugs in K-562 and HL-60 leukemia cell lines. , 2003, Biochemical pharmacology.

[11]  K. Chiba,et al.  A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. , 1998, The Journal of pharmacology and experimental therapeutics.

[12]  D. Waxman,et al.  Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. , 1997, Cancer research.

[13]  P. Nowell,et al.  Association of CYP3A4 genotype with treatment-related leukemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  N. Osheroff,et al.  Reciprocal DNA topoisomerase II cleavage events at 5′-TATTA-3′ sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing , 2003, Oncogene.

[15]  Y. Pommier,et al.  Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. , 2001, Biochemistry.

[16]  H. Yamazaki,et al.  Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. , 2003, Biochemical pharmacology.

[17]  N. Osheroff,et al.  Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. , 2000, Progress in nucleic acid research and molecular biology.

[18]  C. Felix,et al.  Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. , 2001, Journal of mass spectrometry : JMS.

[19]  P. Zaphiropoulos,et al.  The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. , 2000, Gene.

[20]  H. Pinedo,et al.  Mechanism of action of antitumor drug etoposide: a review. , 1988, Journal of the National Cancer Institute.

[21]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[22]  E. Cook,et al.  Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. , 2004, Blood.

[23]  R. A. Coleman,et al.  Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[24]  J. Raucy.  Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[25]  E L LeCluyse,et al.  Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[26]  M. Relling,et al.  O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. , 1994, Molecular pharmacology.

[27]  C. Felix,et al.  Plasma Etoposide Catechol Increases in Pediatric Patients Undergoing Multiple-Day Chemotherapy with Etoposide , 2004, Clinical Cancer Research.

[28]  B. Wouters,et al.  Apoptosis, p53, and tumor cell sensitivity to anticancer agents. , 1999, Cancer research.

[29]  Evans We,et al.  Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins. , 1993 .

[30]  J. Lankelma,et al.  Role of the semi-quinone free radical of the anti-tumour agent etoposide (VP-16-213) in the inactivation of single- and double-stranded phi X174 DNA. , 1990, British Journal of Cancer.

[31]  S. Ben-Neriah,et al.  Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients , 2005, Leukemia.

[32]  M. Ingelman-Sundberg,et al.  Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[33]  M. Vilarem,et al.  Sequence of the 5'-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7. , 1994, Biochemical and biophysical research communications.

[34]  M. Relling,et al.  Human cytochrome P450 metabolism of teniposide and etoposide. , 1992, The Journal of pharmacology and experimental therapeutics.

[35]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.